BD secures FDA 510(k) clearance for EnCor EnCompass system
BD expects to bring the system to market in early 2026.
16 January 2026
16 January 2026
BD expects to bring the system to market in early 2026.
The study consists of an open-label AXS-14 treatment period followed by a randomised, double-blind treatment period.
Agenus has provided Zydus with exclusive rights to develop and commercialise BOT/BAL in India and Sri Lanka.
MedPro contributes national market coverage and commercialisation experience in healthcare technology.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.